Description: Actuaries historically modeled new launches in pharmaceuticals by anticipating the expected change to the market basket. This became more complicated with the recent launches of gene and cell therapies as they address rare diseases. Rare conditions have low total member volume to study and some do not currently have a diagnosis code to identify them within claims data. Addressing this modeling challenge has been growing more important in the recent years with the number of therapies launching. What has the health care industry, and more specifically health care, done to enhance modeling and how should this be altered for the future? Additionally, historic modeling has sometimes incorporated a level of direct medical treatment cost offsets where studies have shown lower treatment costs are achievable. Can gene and cell financial modeling include cost offsets as well? And if so, what are suggested precautions or limitations to this effort?

Description: Enjoy an in-depth walkthrough of the facets of the lab testing world in this webcast. The agenda will include a discussion on genetic testing, which focuses on its general background, current trends and tests in the pipeline, as well as a focus on the approaches to achieve savings in lab testing. Finally, expect to check out sample actuarial analyses that will be used to identify areas of focus in lab management. Join us and take a deeper look into lab work in the actuarial health industry.

Description: This report explores AI bias in insurance and health data, highlighting the ethical role of actuaries and offering cross-disciplinary guidance for fairer decision-making systems.

Description: This report analyzes insurance product design, morbidity trends, and pricing models for individuals with pre-existing illnesses in China to improve coverage for substandard health populations.

Description: An analysis of U.S. mortality trends by socioeconomic category from 1982 to 2023, emphasizing the continuing effects of the COVID-19 pandemic on mortality disparities.

Description: This report covers the latest emerging trends in U.S. population mortality. The SOA relied upon data furnished by the Centers for Disease Control and Prevention (CDC). Observations are based on the CDC’s recent release of 2020 mortality experience, along with prior mortality experience data from 1999 through 2019.

Description: The Mortality and Longevity and Catastrophe and Climate Strategic Research Programs are pleased to make available a report summarizing an expert panel brought together to discuss the impact of wildfires on U.S. health and life insurers.

Description: This report evaluates the long-term mortality consequences of the COVID-19 pandemic from a cohort-based perspective using historical mortality data.

Description: Healthcare cost trends remain a cornerstone of actuarial practice and forecasting for employer-sponsored health plans. This session will examine recent and emerging healthcare drivers of medical and prescription drug trends using data and methodologies drawn from two research efforts focusing on projecting trends and total cost of care.

Description: A summary recap of the recent SOA Health Conference held in Dallas, TX in June of 2025. With the intentional use of AI to assist with the summary, this article gives a good overview of the recent conference with personal commentary from one of the attendees.